Trans-3-Amino-4-Hydroxy-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

In the bulk synthesis of dipeptidyl peptidase-4 (DPP-4) inhibitors, the trans-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester serves as a pivotal chiral pool entry for constructing the (2S,4S)-4-fluoropyrrolidine-2-carbonitrile pharmacophore. The Boc-protected amino alcohol is first subjected to a Mitsunobu-type deoxyfluorination employing diethylaminosulfur trifluoride (DAST) or, for pilot-plant safety, the more thermally stable bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®) in dichloromethane at -20°C to -10°C. The molar stoichiometry is tightly controlled at 1.0:1.05 substrate-to-fluorinating agent to minimize elimination by-products that erode enantiomeric purity. After quenching in aqueous potassium carbonate and extractive workup, the fluorinated intermediate is telescoped into a Boc deprotection using methanolic HCl at 0–5°C, capturing the liberated isobutylene in a chilled scrubber to comply with process safety standards under NFPA 45. The resultant hydrochloride salt is cyanated with sodium cyanide in DMF at 60°C, yielding the nitrile which, upon re-protection or direct coupling, is incorporated into the final drug substance. At this stage, the product stream is monitored by chiral HPLC on a Chiralpak AD-H column (4.6 × 250 mm, hexane/2-propanol 90:10, 0.8 mL/min) to confirm enantiomeric excess above 99.5%, a pre-requisite for API manufacture under ICH Q11. Batch records from dedicated multi-purpose plants employing glass-lined reactors (DIN 28121) indicate that residual fluoride ion must be reduced below 10 ppm via calcium carbonate filtration to avoid corrosion in downstream stainless steel equipment. Environmental compliance requires scrutiny of the by-product diethylamine hydrofluoride; neutralization with calcium hydroxide and precipitation of calcium fluoride before aqueous discharge aligns with EU Directive 2010/75/EU on industrial emissions. The final fluoropyrrolidine nitrile enters the drug substance supply chain for type 2 diabetes management under an FDA drug master file.

Why Does the trans-3-Amino-4-hydroxypyrrolidine Scaffold Appear in Macrocyclic Protease Inhibitors?

The synthesis of hepatitis C virus NS3/4A protease inhibitors such as grazoprevir and voxilaprevir exploits the dual functionality of the trans-3-amino-4-hydroxy-pyrrolidine core to construct the macrocyclic proline ether or amine linkages. In a documented kilo-scale process, the tert-butyl carbamate is deprotected with trifluoroacetic acid (TFA) in dichloromethane (1:1 v/v) in the presence of triisopropylsilane as a carbocation scavenger, maintaining the internal reaction temperature below 5°C to suppress TFA esterification of the secondary alcohol. The resulting amino alcohol, isolated as its trifluoroacetate salt, immediately reacts with a chloroformate-activated quinoline acid in a two-phase n-butyl acetate–aqueous sodium bicarbonate system at 0–10°C, achieving carbamate formation at the pyrrolidine nitrogen with less than 2% O-acylation by-product. Coupling to a cyclopropyl-containing vinyl bromide partner via a Buchwald–Hartwig amination using Pd₂(dba)₃ and XPhos in toluene at 100°C demands rigorous exclusion of oxygen (dissolved O₂ < 0.5 ppm) to prevent catalyst deactivation. The hydroxyl group on the pyrrolidine ring is subsequently alkylated with 1.3 equivalents of 1-bromo-3-chloropropane in the presence of sodium hydride in tetrahydrofuran at -5°C to avoid ring-opening, furnishing the tether that will ultimately enable ring-closing metathesis. The RCM step uses a Grubbs second-generation catalyst (2 mol%) in degassed toluene at 80°C under a gentle nitrogen sweep to remove ethylene; the concentration is held at 0.01 M to favor macrocyclization over oligomerization, a parameter verified by real-time ReactIR monitoring of the vinyl C-H stretch at 910 cm⁻¹. Post-catalysis, residual ruthenium is scavenged with activated carbon (Norit SX Plus) and silica-bound imidazolidine thione to reach a specification of <10 µg/g Ru in the isolated intermediate, consistent with ICH Q3D elemental impurity guidelines. The final deprotection and coupling to a sulfamide side chain yield the macrocyclic inhibitor; the pyrrolidine-derived segment imparts the necessary P2 proline interaction with the S2 enzyme subsite, as corroborated by X-ray co-crystal structures deposited in the Protein Data Bank.

Chiral Phosphoramidite Ligands for Industrial Asymmetric Hydrogenation

The enantiomerically pure trans-amino alcohol, after Boc removal, condenses with 3,3′-diphenyl-1,1′-binaphthyl-2,2′-diyl phosphorochloridite in tetrahydrofuran containing pyridine at -30°C to afford monodentate phosphoramidite ligands tailored for rhodium-catalyzed asymmetric hydrogenation of α-dehydroamino acid esters. The ligand manufacturing process requires the intermediate to be dried to a water content below 50 ppm by Karl Fischer titration to prevent phosphorochloridite hydrolysis; accordingly, the amino alcohol is azeotropically dried with toluene and stored under argon. In a typical hydrogenation protocol, the in situ-formed Rh(COD)₂BF₄–ligand complex at a substrate-to-catalyst (S/C) ratio of 10,000 reduces methyl 2-acetamidoacrylate in methanol under 10 bar H₂ at 25°C, furnishing N-acetylalanine methyl ester with optical yields exceeding 97% ee. The table below summarizes performance across several substrate types encountered in custom synthesis campaigns, reflecting data aggregated from multiple kilo-laboratory runs with in-process chiral GC analysis using an Astec Chiraldex B-PM column.

The phosphoramidite ligand is sensitive to hydrolysis in protonic solvents; therefore, the hydrogenation must be conducted in anhydrous methanol (H₂O <0.01%). At the termination of the reaction, the ligand can be recovered from the methanolic phase by concentrating and precipitating with hexane, albeit with a gradual erosion of ee in consecutive recycles beyond five cycles. Process safety evaluations highlight that the gas-liquid mass transfer must sustain a k_La greater than 0.1 s⁻¹ at 10 bar, achievable in a Biazzi hydrogenator with a hollow-shaft agitator. Complete removal of the chiral ligand traces from the product is validated by ³¹P NMR with a detection limit of 0.5 mol%. The trans-configuration of the pyrrolidine ring is critical: cis-epimers yield ligands that produce racemic products under identical hydrogenation conditions, as confirmed by stereochemical studies employing circular dichroism spectroscopy.

The deployment of the unprotected trans-3-amino-4-hydroxypyrrolidine as an organocatalyst in direct asymmetric aldol additions demands meticulous control over the acid-base stoichiometry during Boc removal. Treatment of the tert-butyl carbamate with methanesulfonic acid in ethyl acetate at room temperature liberates the free amine, which is immediately partitioned into aqueous sodium hydroxide and extracted into THF. Neutralization must proceed to a pH window of 7.8–8.2 to deprotonate the secondary ammonium salt without generating a hydroxide concentration that catalyzes air oxidation of the amine. Early reports describe that the catalyst, used at 10 mol% loading, mediates the reaction between 4-nitrobenzaldehyde and acetone in DMSO at 5°C to give the β-hydroxy ketone adduct in 89% yield and 94% ee after 48 hours. The pyrrolidine amine forms an enamine with acetone, while the neighboring hydroxyl group directs the aldehyde electrophile through a network of hydrogen bonds, locking the Zimmerman–Traxler transition state. Excess water (> 1 equivalent relative to catalyst) collapses the catalytic activity because it disrupts the H-bonded assembly; hence all solvents are dried over molecular sieves 3A and the reaction environment is maintained under argon at relative humidity ≤ 5%. On pilot scale, the catalyst is recovered by acidification and extraction, though its activity drops by approximately 20% after each cycle owing to gradual N-oxidation. Stability studies by differential scanning calorimetry show that the free amino alcohol undergoes an exothermic decomposition above 160°C, which is well outside normal operating regimes but relevant for safety case assessment per ASTM E537. The organocatalytic approach has been extended to Michael additions of dimethyl malonate to β-nitrostyrene, affording the adduct in 86% ee, though the catalytic turnover is slower, requiring 24 hours at ambient temperature. Impurity profiling via LC-MS identifies a minor pyrrolidine N-formyl by-product arising from DMSO degradation; switching to sulfolane as co-solvent eliminates this pathway and raises the ee to 96%. Published data for this specific pyrrolidine-based organocatalyst in large-scale continuous flow formats is limited, but initial attempts in a Corning® Advanced-Flow™ reactor indicate residence time distributions that shrink catalyst consumption by 35% relative to batch due to superior heat and mass transfer.

Tropane Alkaloid Synthesis via Intramolecular Ring-Closing Metathesis

The 8-azabicyclo[3.2.1]octane skeleton of tropane alkaloids like cocaine and atropine can be constructed from the trans-3-amino-4-hydroxypyrrolidine template through a sequence that begins with O-allylation and N-allylation. In a documented medicinal chemistry route, the tert-butyl carbamate is removed with HCl in dioxane, and the resulting ammonium salt is free-based with triethylamine in acetonitrile. Sequential alkylation with allyl bromide (2.2 equivalents) in the presence of potassium carbonate and a catalytic amount of tetrabutylammonium iodide at 60°C yields a diallylated pyrrolidine intermediate. After purification by flash chromatography, the diene is subjected to ring-closing metathesis using the Hoveyda–Grubbs II catalyst (1 mol%) in toluene at 110°C under high dilution (0.005 M). The reaction progresses to full conversion within 2 hours, as monitored by GC, and produces the tropane core in 72% isolated yield after distillation. Residual ruthenium levels are reduced to <5 ppm by stirring with QuadraSil® MP scavenger for 6 hours at 50°C. The hydroxyl group at C-3 of the pyrrolidine ring becomes the equatorial hydroxyl in the tropane, which can be oxidized to the ketone for further functionalization. In parallel, the amino group at C-3 is transformed into the tropane secondary amine after a Cope elimination sequence. This route has been adapted in a current good manufacturing practice (cGMP) setting for the production of a muscarinic acetylcholine receptor antagonist intermediate; the critical process parameter is the drying of the diallyl intermediate to KF < 200 ppm to avoid catalyst decomposition. The enantiomeric purity of the tropane product is correlated directly with the enantiomeric excess of the starting Boc-amino alcohol, with no epimerization observed under the metathesis conditions, as confirmed by chiral SFC on a Chiralpak IG-3 column. An ICH Q3C residual solvent specification for the final intermediate limits allyl bromide to 50 ppm and toluene to 100 ppm, necessitating a rectification step on a wiped-film evaporator at 80°C/5 mbar.

When the trans-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester is utilized as the starting point for the (S,S)-2,8-diazabicyclo[4.3.0]nonane side chain of moxifloxacin, the stereochemical integrity of both chiral centers in the pyrrolidine ring must be preserved across a multi-step reductive amination and cyclization sequence. The ketone required for ring expansion is introduced by a Jones oxidation of the hydroxyl group, forming the 3-amino-4-oxo-pyrrolidine-1-carboxylate tert-butyl ester. The oxidation is performed in acetone with 1.5 equivalents of Jones reagent at 0–5°C, arresting the reaction at the ketone stage before over-oxidation to the acid. The crude ketone is immediately dissolved in methanol and subjected to reductive amination with N-benzylglycine ethyl ester and sodium cyanoborohydride at pH 5–6, yielding the corresponding amino acid derivative with a pyrrolidine scaffold now functionalized for cyclization. After saponification and activation with isobutyl chloroformate, intramolecular acylation forms the seven-membered ring lactam, generating the fused bicyclic core. Hydrogenolysis of the benzyl protecting group over 10% Pd/C at 3 bar H₂ in ethanol provides the secondary amine, which upon Boc re-protection gives the target bicyclic intermediate in an overall yield of 48% from the starting pyrrolidine. This intermediate is then coupled with the quinolonecarboxylic acid nucleus via a mixed anhydride method to complete moxifloxacin. Throughout the process, diastereomeric purity is assured by ¹H NMR integration of the bridgehead proton signals and by HPLC on a Crownpak CR(+) column with aqueous perchloric acid (pH 2.0)/acetonitrile 90:10. A process hazard analysis under OSHA 29 CFR 1910.119 identifies the Jones oxidation as the most energetic step (adiabatic temperature rise 48 K); thus, the oxidation is operated in a semi-batch mode with slow addition of Jones reagent while maintaining the jacket temperature at -2°C. Residual chromium in the isolated intermediate is controlled to <5 ppm by treatment with EDTA-modified silica gel, aligning with the oral permissible daily exposure limits for chromium(III) in pharmaceutical products per ICH Q3D. The documented supply chain for this chiral intermediate under REACH registration relies on the trans-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester meeting a purity specification of ≥99.0 area% and single unknown impurity ≤0.10%, with a certificate of analysis released against a USP reference standard when the product is designated for a marketed formulation.